[Neurobiology in the neuropharmacology of antipsychotic drugs].
Tassin
J P
JP
Collège de France Inserm U 114, 11, place Marcelin Berthelot, 75231 Paris 05.
D058671:Adrenergic beta-1 Receptor Antagonists; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D009415:Nerve Net / Q000187:drug effects / Q000503:physiopathology; D009638:Norepinephrine / Q000502:physiology; D044402:Receptor, Serotonin, 5-HT2A / Q000502:physiology; D018342:Receptors, Adrenergic, beta-1 / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012701:Serotonin / Q000502:physiology; D058830:Serotonin 5-HT2 Receptor Antagonists
D058671:Adrenergic beta-1 Receptor Antagonists; D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D044402:Receptor, Serotonin, 5-HT2A; D018342:Receptors, Adrenergic, beta-1; D017448:Receptors, Dopamine D2; D058830:Serotonin 5-HT2 Receptor Antagonists; D012701:Serotonin; D004298:Dopamine; D009638:Norepinephrine